Back to companies

Dicerna Pharmaceuticals Inc: Overview

Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver. Dicerna’s GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. The company also develops therapies to treat diseases linking the liver includes rare, viral infections, chronic liver, and cardiovascular diseases. Dicerna is headquartered in Lexington, Massachusetts, the US.

Headquarters United States of America

Address 75 Hayden Avenue, Lexington, Massachusetts, 02421


Telephone 1 617 6218097

No of Employees 302

Industry Pharmaceuticals and Healthcare

Revenue (2020) $164.3M

   

   

Access premium data and analytics for Dicerna Pharmaceuticals Inc

40+

Pipeline Drugs

Identify which of Dicerna Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Dicerna Pharmaceuticals Inc’s relevant decision makers and contact details.

11+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

10+

Clinical Trials

Determine Dicerna Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

50+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Dicerna Pharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Nedosiran (formerly DCR-PHXC)
RG6346 (formerly DCR-HBVS)
Belcesiran (formerly DCR-A1AT)
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Contracts/Agreements In November, the company entered into an agreement to be acquired by Novo Nordisk for US$3.3billion.
2021 Regulatory Approval In July, the company secured the US FDA clearance of IND application for DCR-AUD to treat people with alcohol use disorder.
2019 Contracts/Agreements In November, the company entered into a partnership with Novo Nordisk to develop RNAi therapies to treat liver-related cardio-metabolic diseases by using GalXC RNAi platform technology.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Dicerna Pharmaceuticals Inc Arrowhead Pharmaceuticals Inc Cumberland Pharmaceuticals Inc Lipocine Inc Humanigen Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Lexington Pasadena Nashville Salt Lake City Short Hills
State/Province Massachusetts California Tennessee Utah New Jersey
No. of Employees 302 329 83 13 11
Entity Type Private Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
J. Kevin Buchi Chairman Executive Board 2019 65
Douglas M. Fambrough, III President; Chief Executive Officer; Director Executive Board 2020 52
Douglas Pagan Chief Financial Officer Senior Management 2020 49
Jim Weissman Executive Vice President; Chief Operating Officer Senior Management 2019 59
Rob Ciappenelli Chief Strategy Officer Senior Management 2021 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?